• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    2/13/24 5:17:07 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ISPC alert in real time by email
    SC 13G/A 1 tm61.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    iSpecimen Inc.
    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

    45032V108
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    CUSIP No. 45032V108

    1
    NAME OF REPORTING PERSONS
     
    OBF Investments, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     
    (a) ☐
    (b) ☐
     
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Florida
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    841,981
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    841,981
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    841,981
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    □
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.3% (1)
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    OO

    (1)  Percent of class is calculated based on 9,075,807 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 2, 2023.

    CUSIP No. 45032V108

    1
    NAME OF REPORTING PERSONS
     
    George H. Scholl
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     
    (a) ☐
    (b) ☐
     
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    845,231 (1)
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    845,231 (1)
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    845,231 (1)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    □
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.3% (1) (2)
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN

    (1)
    Includes the 841,981 shares of common stock held by OBF Investments, LLC. As the President and Chief Executive Officer of OBF Investments, LLC, Mr. Scholl
    may be deemed to beneficially own the 841,981 shares of common stock held by OBF Investments, LLC.  Also includes a total of 3,250 shares of common stock issued upon the vesting and settlement of restricted stock units (“RSUs”) previously awarded to Mr. Scholl as compensation for his service as a director of the Issuer.

    (2)  Percent of class is calculated based on 9,075,807 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 2, 2023.

    CUSIP No. 45032V108

    Item 1(a).
    Name of Issuer:

    iSpecimen Inc. (the "Issuer")

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    450 Bedford Street
    Lexington, MA 02420

    Item 2(a).
    Name of Person Filing:

    OBF Investments, LLC and George H. Scholl

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of OBF Investments, LLC and George H. Scholl is c/o OBF Investments, LLC, 10100 Dr. Martin Luther King Jr. St. N., St. Petersburg, Florida 33716.

    Item 2(c).
    Citizenship:

    OBF Investments, LLC is a limited liability company organized and existing under the laws of the State of Florida.

    Mr. Scholl is a United States citizen.

    Item 2(d).
    Title of Class of Securities:

    Common Stock, par value $0.0001 per share

    Item 2(e).
    CUSIP Number:

    45032V108

    Item 3.
    If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b), or (c), check whether the person filing is a:

    (a)
    [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);

    (b)
    [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)
    [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);


    CUSIP No. 45032V108
    (d)
    [ ] Investment company registered under Section 8 of the Investment     Company Act of 1940 (15 U.S.C 80a-8);

    (e)
    [ ] An investment adviser in accordance with § 240.13d-l(b)(l)(ii)(E);

    (f)
    [ ] An employee benefit plan or endowment fund in accordance with § 240.13d -1 (b)(1)(ii)(F);

    (g)
    [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

    (h)
    [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)
    [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)
    [ ] A non-U.S. institution in accordance with § 240.13d-l(b)(l)(ii)(J);

    (k)
    [ ] Group, in accordance with § 240.13d-l(b)(l)(ii)(K).

    If filing as a non-U.S. institution in accordance with§ 240.13d-l(b)(l)(ii)(J), please specify the type of institution: ________

    Not applicable.

    Item 4        Ownership:

    OBF Investments, LLC

    (a)
    Amount Beneficially Owned:  841,981 shares of common stock.

    (b)
    Percent of Class:  9.3% , which is calculated based on 9,075,807 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 2, 2023.

    George Scholl:

    (a)
    Amount Beneficially Owned:  845,231 shares of common stock.

    Includes the 841,981 shares of common stock held by OBF Investments, LLC. As the President and Chief Executive Officer of OBF Investments, LLC, Mr. Scholl may be deemed to beneficially own the 841,981 shares of common stock held by OBF Investments, LLC.

    Also includes a total of 3,250 shares of common stock issued upon the vesting and settlement of restricted stock units (“RSUs”) previously awarded to Mr. Scholl as compensation for his service as a director of the Issuer.

    (b)
    Percent of Class:  9.3%, which is calculated based on 9,075,807 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 2, 2023.


    CUSIP No. 45032V108

    (c)
    Number of shares as to which such person has:


    (i)
    sole power to vote or to direct the vote:  845,231


    (ii)
    shared power to vote or to direct the vote:  0


    (iii)
    sole power to dispose or to direct the disposition of:  845,231


    (iv)
    shared power to dispose or to direct the disposition of:  0

    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not Applicable

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

    Item 8.
    Identification and Classification of Members of the Group:

    Not Applicable

    Item 9.
    Notice of Dissolution of Group:

    Not Applicable

    CUSIP No. 45032V108

    Item 10.
    Certification:

    Not Applicable

    Exhibits.
    99.1 Joint Filing Agreement – Previously Filed




    CUSIP No. 45032V108

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date:  February 13, 2024


    OBF Investments, LLC


    /s/George H. Scholl
    By: George H. Scholl
    Its: President and Chief Executive Officer


    /s/George H. Scholl
     George H. Scholl
    Get the next $ISPC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPC

    DatePrice TargetRatingAnalyst
    1/4/2022$20.00Buy
    Craig-Hallum
    11/22/2021$10.00 → $12.00Buy
    EF Hutton
    More analyst ratings

    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig-Hallum initiated coverage on iSpecimen with a new price target

    Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00

    1/4/22 7:34:53 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EF Hutton reiterated coverage on iSpecimen with a new price target

    EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously

    11/22/21 11:51:50 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Liang Yuying

    3 - iSpecimen Inc. (0001558569) (Issuer)

    1/30/25 4:05:21 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Lim Robert Bradley

    3 - iSpecimen Inc. (0001558569) (Issuer)

    12/13/24 6:30:47 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Dhaliwal Avtar

    3 - iSpecimen Inc. (0001558569) (Issuer)

    9/30/24 6:01:18 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform

    Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ:ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's next-generation, cloud-native architecture, expected to deliver immediate value through:Infrastructure-as-Code (IaC): bui

    8/21/25 8:00:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow

    Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ:ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.iSpecimen has retained WestPark Capital to advise on the initiative with any funds that may be allocated or raised to be earmarked for building a digital asset treasury that will support long-term value creation and fuel innovation across iSpecimen's digital infrastructure. To

    8/7/25 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market

    WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR

    8/4/25 6:45:12 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iSpecimen Inc. (0001558569) (Filer)

    8/21/25 8:00:35 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-1 filed by iSpecimen Inc.

    S-1 - iSpecimen Inc. (0001558569) (Filer)

    8/20/25 3:40:43 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by iSpecimen Inc.

    10-Q - iSpecimen Inc. (0001558569) (Filer)

    8/14/25 4:05:51 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Financials

    Live finance-specific insights

    View All

    iSpecimen Reports Second Quarter 2024 Results

    Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for

    8/6/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

    LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call  Date:Tuesday, August 6, 2024  Time:8:30 a.m. Eastern Time  Live Call:+1-800-717-1738

    7/25/24 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Reports First Quarter 2024 Results

    LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C

    5/7/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Leadership Updates

    Live Leadership Updates

    View All

    iSpecimen Appoints Eric Langlois as Chief Revenue Officer

    LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca

    1/24/23 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Names Tracy Curley as Chief Executive Officer

    LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi

    1/10/23 1:11:01 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Appoints Joseph J. Basile to Board of Directors

    LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato

    12/5/22 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/24 5:17:07 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D filed by iSpecimen Inc.

    SC 13D - iSpecimen Inc. (0001558569) (Subject)

    4/17/23 1:27:18 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/23 4:04:55 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care